GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.609
-0.020 (-3.24%)
At close: Dec 5, 2025, 4:00 PM EST
0.603
-0.006 (-1.05%)
After-hours: Dec 5, 2025, 7:03 PM EST

GT Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Net Income
-9.1-13.16-7.6-20.88-58.01-28.3
Upgrade
Other Amortization
-----0.32
Upgrade
Asset Writedown & Restructuring Costs
-----0.06
Upgrade
Loss (Gain) From Sale of Investments
-0--0.050.030.03-
Upgrade
Stock-Based Compensation
0.390.232.27.6533.930.27
Upgrade
Other Operating Activities
-1.28-0.75-5.23-0.020.5117.98
Upgrade
Change in Accounts Payable
-1.270.941.96-2.037.08-0.84
Upgrade
Change in Other Net Operating Assets
-0.12-0.16-0.140.040.863.24
Upgrade
Operating Cash Flow
-11.36-12.9-8.85-15.22-15.61-7.26
Upgrade
Investment in Securities
012.89-2.0112.15-23.04-
Upgrade
Investing Cash Flow
012.89-2.0112.15-23.04-
Upgrade
Short-Term Debt Issued
----1.2112.53
Upgrade
Total Debt Issued
----1.2112.53
Upgrade
Net Debt Issued (Repaid)
----1.2112.53
Upgrade
Issuance of Common Stock
1.052.986.27-41.11-
Upgrade
Repurchase of Common Stock
----0.22--
Upgrade
Financing Cash Flow
7.472.986.27-0.2242.3212.53
Upgrade
Net Cash Flow
-3.892.97-4.59-3.33.675.27
Upgrade
Free Cash Flow
-11.36-12.9-8.85-15.22-15.61-7.26
Upgrade
Free Cash Flow Per Share
-4.01-6.80-6.57-14.32-16.63-49.68
Upgrade
Cash Interest Paid
--0.21---
Upgrade
Levered Free Cash Flow
-11.02-9.62-4.68-10.91-0.82-3.42
Upgrade
Unlevered Free Cash Flow
-11.02-9.62-4.55-10.9-0.38-1.66
Upgrade
Change in Working Capital
-1.380.781.83-1.997.942.4
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.